Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot3 - STU 1 Ballot 3 World

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot3 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

EvidenceVariable: Progression-free survival (NCT05327010)

Computable Name:

version: 2; Last updated: 2026-07-27 13:49:52+0000

Profile: VariableDefinition

ArtifactPublicationStatus: Active

url: https://fevir.net/resources/EvidenceVariable/583773

identifier: FEvIR Object Identifier/583773, FEvIR Linking Identifier/NCT05327010-secondaryOutcome-2

name: Progression_free_survival_NCT05327010

title: Progression-free survival (NCT05327010)

citeAs:

Progression-free survival (NCT05327010) [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 583773. Revised 2026-07-27. Available at: https://fevir.net/resources/EvidenceVariable/583773. Computable resource at: https://fevir.net/resources/EvidenceVariable/583773#json.

status: Active

author: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter:

publisher: Computable Publishing LLC

contact: support@computablepublishing.com

description:

Assessed by radiographic disease assessments per RECIST v1.1.

copyright:

Copyright the Authors else Computable Publishing LLC. Noncommercial use permitted with CC BY-NC-SA 4.0 (https://creativecommons.org/licenses/by-nc-sa/4.0/). Commercial use permitted as agreed in Terms of Use (https://fevir.net/termsofuse).

Definitions

-Concept
*Progression-free survival Assessed by radiographic disease assessments per RECIST v1.1.

handling: Evidence variable handling not specified

Timings

-Text
*From start of treatment to time of progression or death, whichever occurs first, assessed up to 2 years